Details
Stereochemistry | ACHIRAL |
Molecular Formula | C4H8O3 |
Molecular Weight | 104.1045 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCCC(O)=O
InChI
InChIKey=SJZRECIVHVDYJC-UHFFFAOYSA-N
InChI=1S/C4H8O3/c5-3-1-2-4(6)7/h5H,1-3H2,(H,6,7)
Sodium oxybate is the sodium salt of gamma-hydroxybutyrate (GHB), an endogenous metabolite of gamma-aminobutyric acid (GABA) a major inhibitory neurotransmitter. Evidence suggests a role for GHB as a neuromodulator/neurotransmitter. Under endogenous conditions and concentrations, and depending on the cell group affected, GHB may increase or decrease neuronal activity by inhibiting the release of neurotransmitters that are co-localised with GHB. After exogenous administration, most of the observed behavioural effects appear to be mediated via the activity of GHB at GABA(B) receptors, as long as the concentration is sufficient to elicit binding, which does not happen at endogenous concentrations. Xyrem (sodium oxybate) oral solution is indicated for the treatment of cataplexy in narcolepsy and excessive daytime sleepiness (EDS) in narcolepsy.
CNS Activity
Originator
Sources: Laborit H. (1964) Sodium 4-hydroxybutyrate. J Neuropharmacol 32: 433–452
Curator's Comment: Sodium oxybate (sodium salt of gamma-hydroxybutyrate (GHB) was first described as a possible precursor of GABA that could cross the blood-brain barrier [Laborit, 1964]. Further elucidation proved it an endogenous metabolite of GABA [Roth and Giarman, 1969] with a turnover of 0.16% of GABA being converted to GHB [Maitre, 1997] reference retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382678/
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2111463 Sources: http://pp.jazzpharma.com/pi/xyrem.en.USPI.pdf |
100.0 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | XYREM Approved UseXYREM® (sodium oxybate) oral solution is a central nervous system depressant indicated for the treatment of:
• Cataplexy in narcolepsy
• Excessive daytime sleepiness (EDS) in narcolepsy Launch Date2002 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
54 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1389947 |
25 mg/kg 2 times / day multiple, oral dose: 25 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
23 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
12.5 mg/kg single, oral dose: 12.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
23 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
25 mg/kg single, oral dose: 25 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
20 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
50 mg/kg single, oral dose: 50 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3122 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1389947 |
25 mg/kg 2 times / day multiple, oral dose: 25 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
905 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
12.5 mg/kg single, oral dose: 12.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1271 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
25 mg/kg single, oral dose: 25 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1565 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
50 mg/kg single, oral dose: 50 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
27 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1389947 |
25 mg/kg 2 times / day multiple, oral dose: 25 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
20 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
12.5 mg/kg single, oral dose: 12.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
22 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
25 mg/kg single, oral dose: 25 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
23 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
50 mg/kg single, oral dose: 50 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
99% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8299669 |
12.5 mg/kg single, oral dose: 12.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
4-HYDROXYBUTANOIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 29, 35 |
no [IC50 >300 uM] | |||
Page: 29, 35 |
no [IC50 >300 uM] | |||
Page: 29, 35 |
no [IC50 >300 uM] | |||
Page: 29, 35 |
no [IC50 >300 uM] | |||
Page: 29, 35 |
no [IC50 >300 uM] | |||
Page: 29, 35 |
no [IC50 >300 uM] |
PubMed
Title | Date | PubMed |
---|---|---|
Diagnosis of unsuspected gamma hydroxy-butyrate poisoning by proton NMR. | 2001 |
|
Preparation and characterization of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) microspheres for the sustained release of 5-fluorouracil. | 2001 |
|
Properties, modifications and applications of biopolyesters. | 2001 |
|
[The new drugs: ecstasy, GHB. Update for practitioners]. | 2001 Dec |
|
Gamma-hydroxybutyrate withdrawal syndrome. | 2001 Feb |
|
Diazepam in the treatment of GHB dependence. | 2001 Feb |
|
Different control of GH secretion by gamma-amino- and gamma-hydroxy-butyric acid in 4-year abstinent alcoholics. | 2001 Feb 1 |
|
Gamma-hydroxybutyrate overdose and physostigmine: teaching new tricks to an old drug? | 2001 Jan |
|
GHB and driving impairment. | 2001 Jul |
|
A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4-butanediol. | 2001 Jul |
|
Baclofen antagonises intravenous self-administration of gamma-hydroxybutyric acid in mice. | 2001 Jul 20 |
|
Characterization of partially transesterified poly(beta-hydroxyalkanoate)s by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. | 2001 Jul-Aug |
|
Patient information. Date rape drugs: what parents should know. | 2001 Jun |
|
It's a rave new world: rave culture and illicit drug use in the young. | 2001 Jun |
|
The Circuit Party Men's Health Survey: findings and implications for gay and bisexual men. | 2001 Jun |
|
Metabolic flux in cellulose batch and cellulose-fed continuous cultures of Clostridium cellulolyticum in response to acidic environment. | 2001 Jun |
|
Dopaminergic changes in human brain following acute exposure to gamma-hydroxybutyrate. | 2001 Jun 12 |
|
[Liquid ecstasy poisoning: study of 22 cases]. | 2001 Jun 16 |
|
Identification and effects of interaction phytotoxic compounds from exudate of Cistus ladanifer leaves. | 2001 Mar |
|
GHB: its use and misuse. | 2001 Mar |
|
Assessment of coronary reperfusion in patients with myocardial infarction using fatty acid binding protein concentrations in plasma. | 2001 Mar |
|
[Acute involuntary intoxication with gamma-hydroxybutyric acid]. | 2001 May |
|
[Gamma-hydroxybutyric acid-ethanolamide (LK 544). The suitability of LK 544 for sedation of patients in intensive care in comparison with midazolam]. | 2001 May |
|
Lack of efficacy of benzodiazepines in treating gamma-hydroxybutyrate withdrawal. | 2001 May |
|
Determination of gamma-hydroxybutyrate in water and human urine by solid phase microextraction-gas chromatography/quadrupole ion trap spectrometry. | 2001 May |
|
Effect of gamma-hydroxybutyric acid on human platelet aggregation in vitro. | 2001 May 1 |
|
GHB: an important pharmacologic and clinical update. | 2001 May-Aug |
|
Inheritance pattern of RAPD markers in Melipona quadrifasciata (Hymenoptera: Apidae, Meliponinae). | 2001 May-Jun |
|
1H NMR spectroscopic investigation of serum and urine in a case of acute tetrahydrofuran poisoning. | 2001 May-Jun |
|
Drug dependence studies and regulations: an overview of the past and present. | 2001 Nov |
|
The chemical interconversion of GHB and GBL: forensic issues and implications. | 2001 Nov |
|
gamma-Hydroxybutyric acid and baclofen decrease extracellular acetylcholine levels in the hippocampus via GABA(B) receptors. | 2001 Nov 2 |
|
Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase. | 2001 Oct |
|
GC-MS determination of gamma-hydroxybutyric acid (GHB) in blood. | 2001 Oct 15 |
|
Discrimination of gamma-hydroxybutyrate and ethanol administered separately and as a mixture in rats. | 2001 Sep |
|
Use of physostigmine in the management of gamma-hydroxybutyrate overdose. | 2001 Sep |
|
Prolonged withdrawal from extreme gamma-hydroxybutyrate (GHB) abuse. | 2001 Sep-Oct |
|
Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. | 2001 Summer |
|
Comonomer unit composition and thermal properties of poly(3-hydroxybutyrate-co-4-hydroxybutyrate)s biosynthesized by Ralstonia eutropha. | 2001 Winter |
|
Purification and characterization of the D-beta-hydroxybutyrate dehydrogenase from dromedary liver mitochondria. | 2002 Jan |
|
Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. | 2002 Mar 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://pp.jazzpharma.com/pi/xyrem.en.USPI.pdf
Initiate dose at 4.5 grams (g) per night administered orally in two equal, divided doses: 2.25 g at bedtime and 2.25 g taken 2.5 to 4 hours later.
Titrate to effect in increments of 1.5 g per night at weekly intervals (0.75 g at bedtime and 0.75 g taken 2.5 to 4 hours later).
Recommended dose range: 6 g to 9 g per night orally.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11313294
Curator's Comment: gamma-hydroxybutyrate (GHB) activates both pre- and postsynaptic GABA(B)-receptors in neocortical neurons participating in fast synaptic transmission, leading to a powerful depression of neocortical network activity.
Unknown
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EPA PESTICIDE CODE |
621757
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
NCI_THESAURUS |
C687
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
FDA ORPHAN DRUG |
5384
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
FDA ORPHAN DRUG |
694619
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
LIVERTOX |
NBK548588
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
LOINC |
59209-7
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
LOINC |
28041-2
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
LOINC |
28065-1
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
FDA ORPHAN DRUG |
26387
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
LOINC |
28038-8
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
FDA ORPHAN DRUG |
85894
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
LOINC |
29868-7
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
LOINC |
74920-0
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
NDF-RT |
N0000175758
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
LOINC |
47542-6
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
LOINC |
43198-1
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
DEA NO. |
2010
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
LOINC |
50148-6
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
LOINC |
72433-6
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
LOINC |
43197-3
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
LOINC |
44358-0
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
NDF-RT |
N0000175728
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
LOINC |
46085-7
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
NDF-RT |
N0000008501
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
LOINC |
68441-5
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
LOINC |
57746-0
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
LOINC |
68970-3
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
LOINC |
28044-6
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
LOINC |
68440-7
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
||
|
LOINC |
43194-0
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
10413
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
PRIMARY | |||
|
SUB32656
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
PRIMARY | |||
|
DTXSID2074740
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
PRIMARY | |||
|
16724
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
PRIMARY | |||
|
2387302
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
PRIMARY | |||
|
100000125890
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
PRIMARY | |||
|
GAMMA-HYDROXYBUTYRIC ACID
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
PRIMARY | |||
|
30830
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
PRIMARY | |||
|
30IW36W5B2
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
PRIMARY | |||
|
30IW36W5B2
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
PRIMARY | |||
|
C111420
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
PRIMARY | |||
|
4711
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
PRIMARY | |||
|
6927
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
PRIMARY | |||
|
591-81-1
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
PRIMARY | |||
|
m6124
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
PRIMARY | Merck Index | ||
|
DB01440
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
PRIMARY | |||
|
C61773
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
PRIMARY | |||
|
1546380
Created by
admin on Mon Mar 31 17:47:48 GMT 2025 , Edited by admin on Mon Mar 31 17:47:48 GMT 2025
|
ALTERNATIVE | RxNorm |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE INACTIVE (PARENT)
METABOLITE INACTIVE (PARENT)
PARENT (METABOLITE ACTIVE)
PARENT (METABOLITE)
PRODRUG (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)